One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema
One-year outcomes among patients with DME initiating faricimab in clinical practice support the real-world effectiveness and extended durability of treatment.
Authors
- Ayesha Ahmed (ORCID: https://orcid.org/0000-0002-2036-7067)
- Theodore Leng (ORCID: https://orcid.org/0000-0002-8461-3562)
- David Tabano (ORCID: https://orcid.org/0000-0001-7657-0809)
- Amanda E. Downey (ORCID: https://orcid.org/0000-0002-5206-7798)
- Alayna C Myrick
- Erin Zwick (ORCID: https://orcid.org/0000-0001-7174-198X)
- Giulio Barteselli (ORCID: https://orcid.org/0000-0003-0533-1135)
- Rishi P. Singh (ORCID: https://orcid.org/0000-0001-5859-8162)
- Ferhina S. Ali
- Durga S. Borkar
Institutions
- Roche (Switzerland) (CH)
- Duke University (US)
- New York Medical College (US)
- Roche (Canada) (CA)
- San Francisco Department of Public Health (US)
- Cleveland Eye Clinic (US)
- Martin Health System (US)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmic surgery, lasers & imaging retina
- Published
- 2025-11-04
- DOI
- https://doi.org/10.3928/23258160-20250825-02
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00